The US National Institute of Health (NIH) reported that an experimental HIV vaccination regimen was safe but did not offer protection against HIV acquisition. According to the Xinhua news agency, the HPX3002/HVTN 706 or "Mosaico" experiment began in 2019 and enrolled 3,900 participants from Europe, North America, and South America between the ages of 18 and 60.

The experiment was carried out by the Seattle-based Fred Hutchinson Cancer Research Center’s HIV Vaccine Clinical Trials Network, which acquired its funding from the US National Institute of Allergy and Infectious Diseases.

The experimental vaccine regimen was developed by Janssen. On Wednesday, the NIH stated that the purpose of the vaccine was to induce immune responses against a wide variety of global HIV strains. The vaccine was based on "mosaic" immunogens, a vaccine component that contains parts of many HIV subtypes. 

(Source: https://www.daijiworld.com/news/newsDisplay?newsID=1041232 )